Skip to main content
Equibles

KENNEDY CAPITAL MANAGEMENT LLC

Position in LGND — Ligand Pharmaceuticals Inc

CIK 884589 ST LOUIS, MO
Back to LGND Full portfolio

Position in LGND

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$10,542,549
+$8,124,768 QoQ
Shares Held
33,353
-1.5% QoQ
Ownership
0.167%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#84
of 415 holders
Holding Since
Mar 2020
17 quarters on record
Voting authority Sole 93% Shared 0% None 7%

Common Shares in LGND Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

KENNEDY CAPITAL MANAGEMENT LLC holds $451,584,893 across 62 Biotechnology names. LGND ranks #14 (2.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 HALO
Halozyme Therapeutics, Inc.
 544,994 $42,656,680
2 RYTM
Rhythm Pharmaceuticals, Inc.
 193,215 $21,452,661
3 NRIX
Nurix Therapeutics, Inc.
 724,508 $17,576,564
4 CORT
Corcept Therapeutics Inc
 201,979 $17,562,074
5 PTGX
Protagonist Therapeutics, Inc
 134,019 $16,428,049
6 MGTX
MeiraGTx Holdings plc
 1,105,421 $14,934,237
7 ADMA
Adma Biologics, Inc.
 1,755,152 $14,690,622
8 NAMS
NewAmsterdam Pharma Co N.V.
 421,374 $14,280,364

All Filings in LGND

Export CSV
17 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $10,542,549 33,353
2023-12-31 $2,417,781 33,853
2023-09-30 $2,139,084 35,699
2023-06-30 $2,486,296 34,484
2023-03-31 $1,079,051 14,669
2022-12-31 $751,299 11,247
2022-09-30 $969,598 11,260
2022-06-30 $1,004,527 11,259
2022-03-31 $1,204,768 10,710
2021-12-31 $1,670,484 10,815
2021-09-30 $1,559,268 11,192
2021-06-30 $1,556,175 11,862
2021-03-31 $2,278,669 14,947
2020-12-31 $10,948,644 110,092
2020-09-30 $5,413,889 56,797
2020-06-30 $17,399,157 155,558
2020-03-31 $11,841,059 162,831